Applications are invited for an exciting opportunity to join the OHSU Knight Cancer Institute as the Director of the Bone Marrow Transplantation (BMT) program.  Successful candidates will receive a faculty appointment within the Division of Hematology and Medical Oncology. Faculty applicants may be eligible for senior faculty positions, based on external funding and publications, commensurate with experience, as determined by the OHSU School of Medicine. 

The Director of Adult Blood & Marrow Transplantation shall lead all aspects of the BMT program including education, research, and clinical programming. The Adult BMT Director will report to the Head of the Division of Hematology and Medical Oncology. Anticipated institutional collaborative efforts for managing the BMT program will include efforts with the Doernbecher Pediatric BMT Program leader, OHSU Cellular Therapy Program Leader, Hematology & Oncology Division Medical Director, the OHSU Hematology & Oncology Division Quality Director, OHSU Vice President for Oncology Services, as well as members of other Knight Cancer Institute leadership team, to design and execute strategic initiatives. The BMT Director will serve as the Program Director for hematopoietic cellular therapy in accordance with FACT-JACIE Standards. The BMT Director may delegate specific duties to other faculty leaders in support of the BMT program.

1. Clinical Operations. Per FACT-JACIE Standards for Hematopoietic Cellular Therapy: The BMT Director will provide leadership for:
   • Administrative and clinical operations, including serving as Medical Director of the Northwest Marrow Transplant Program, coordinating care between Doernbecher Children’s Hospital and Legacy-Good Samaritan Hospital teams, and to maintain compliance with FACT standards and other regulations and policies.
   • Active management of the clinical program, including quality management, selection and care of recipients and donors, and cell collection and processing. Focus on achieving and maintaining national quality measures is a major focus as well as assuring Center of Excellence status with external payers.
   • Oversight of the medical care provided by members of the clinical program, including verification of the knowledge and skills of members.
   • Currently, shared direction is planned for the OHSU Hematopoietic Cellular Therapy and the Immune Effector Cell therapy programs.
2. Research. The BMT Director will work with the BMT team faculty, along with members of the Knight Cancer Institute clinical research management team, to ensure a broad portfolio of research, including translational research studies and clinical trials. Clinical trials will include institutional investigator initiated studies, as well as those sponsored by pharmaceutical and biotechnology companies as well as to ensure active participation in the BMT Clinical Trials Network and other cooperative groups. Ongoing commitment to maintaining institutional data base and registry will assure ongoing clinical research efforts.
   • BMT Clinical Trials Network
   • SWOG/ NCTN
3. Operations and Finance. The BMT Director will work with the OHSU Hospital Transplant Manager, with the Hematology & Oncology Division and Knight Cancer Institute to develop and execute strategies for focused program areas of excellence and growth and to allocate program-specific resources, including:
   • Faculty recruitment and team expansion
   • Knight strategic planning
   • Value Stream Management
   • Marketing and community outreach
   • CIBMTR registry
4. Education and Faculty Development. The BMT Director will work with other senior BMT team members, to maintain a structure for orientation and continuing education for all program members, including faculty physicians and APPS, fellows and residents, nursing, and pharmacy. The BMT Director will meet with individual faculty to monitor and support their professional development and advancement..  The BMT director will actively recruit faculty to develop the clinical and research programs and will engage in faculty building, retention and development opportunities.  
   • Annual faculty reviews
   • APP leadership meetings
   • Internal and external educational conferences
   • Assure FACT annual educational targets are

BMT Program leadership roles: The following faculty leadership roles are in place or may be created. Collaborative management is anticipated and necessary where these positions will work directly with the BMT Director to effectively implement the program.

• Pediatric Clinical Program Director (joint NWMTP)
• Adult Legacy Good Samaritan Clinical Program Director (joint NWMTP)
• BMT Program Quality Medical Director
• Adult Marrow Collection Facility Medical Director
• Pediatric Marrow Collection Facility Medical Director
• Apheresis Collection Facility Medical Director
• Cell Therapy  Facility Medical Director
• Clinical Director, BMT Program
• Director of Research, BMT
• Program Leader, Immune effector cellular therapy

Accountability for assessing Adult BMT program success and to establish prospective Adult BMT program targets will be assessed annually with Hematology & Oncology Division, OHSU hospital and Knight Cancer Institute leaderships. It is anticipated the position will be made up of the following components: Clinical, teaching research/academic, and inpatient service.